⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMY News
Bristol-Myers Squibb Co.
DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight
prnewswire.com
INSM
AXSM
LLY
BMY
AZN
NVO
JNJ
Proteins & Protein Crystals Market worth $960.37 billion by 2030 | MarketsandMarkets™
prnewswire.com
DHR
MRK
AMGN
LLY
PFE
BMY
TMO
Cellares Raises $257 Million Series D Led by BlackRock and Eclipse to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation
businesswire.com
BMY
Boehringer Ingelheim convenes "Detect the SOS" Collective for public health mission: increase uACR screening among adults with type 2 diabetes and/or high blood pressure to help uncover kidney damage and elevated heart risks
prnewswire.com
BMY
App Test Automation Industry Research 2026 - Global Market Size, Share, Trends, Opportunities, and Forecasts, 2021-2025 & 2026-2031
globenewswire.com
LOGI
MSFT
GOOG
AMZN
IBM
ORCL
INTC
NVDA
CRM
ADBE
SAP
EA
TTWO
ROKU
NFLX
DIS
CMCSA
TCOM
MELI
SHOP
PYPL
UBER
LYFT
DDOG
PANW
CRWD
ZS
NOW
TWLO
SNOW
PLTR
AI
STX
WDC
HPQ
DELL
HPE
QCOM
MRVL
AMD
MU
AMAT
LRCX
KLAC
ASML
GLW
AVGO
NXPI
TER
KEYS
NI
CHKP
FTNT
PPC
LULU
SIRI
BBY
TJX
LOW
HD
CAT
BA
GD
LMT
RTX
HON
GE
MMM
AXP
JPM
BAC
WFC
C
GS
MS
V
MA
PG
KO
PEP
MCD
SBUX
VZ
T
CHTR
TMUS
AMGN
BMY
PFE
JNJ
MRK
ABBV
LLY
GILD
BIIB
REGN
VRTX
AZN
SNY
NVS
XOM
CVX
SHEL
BABA
JD
NTES
PDD
EDU
TAL
BIDU
VIPS
CPRT
Boxing Icon Sugar Ray Leonard Sits Down with Visionary Entrepreneur and Renowned Speaker Sean Callagy for No Holds-Barred Interview on "Unblinded" Podcast
accessnewswire.com
TMUS
DIS
BMY
CRM
MA
Pixelgen Technologies Appoints Chief Commercial Officer to Lead Global Expansion
prnewswire.com
MRK
BMY
RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
prnewswire.com
MRK
LLY
RIGL
AZN
GILD
ABBV
PFE
TMO
BMY
NVS
BIIB
Central Nervous System Therapeutics Market Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031
globenewswire.com
BMY
SNY
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA USA - English USA - English
prnewswire.com
BMY
BIIB